Merck announced on December 16, 2024, the discontinuation of clinical development programs for two experimental cancer drugs, vibostolimab and favezelimab. This decision follows their failure in several trials.
Vibostolimab was being evaluated as an investigational fixed-dose combination with Keytruda in the KeyVibe program, including Phase 3 KeyVibe-003 and KeyVibe-007 trials. Favezelimab was being evaluated in the KEYFORM program.
These discontinuations represent setbacks in Merck's oncology pipeline, impacting its efforts to diversify beyond Keytruda. The company will reallocate resources to other promising assets in its robust pipeline.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.